Last updated on March 2019

Study of Lifileucel ( LN-144) Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Metastatic Melanoma

Brief description of study

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) with Lifileucel infusion (LN-144) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen.

Detailed Study Description

Lifileucel is an autologous adoptive cell transfer therapy that utilizes a TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with metastatic melanoma. The adoptive cell transfer therapy used in this study involves patients receiving a lymphocyte depleting preconditioning regimen, prior to infusion of autologous TIL, followed by the administration of a regimen of IL-2.

Clinical Study Identifier: NCT02360579

Contact Investigators or Research Sites near you

Start Over

Iovance Biotherapeutics Clinical Inquiries

Iovance Investigative Site
Miami Beach, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.